Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN ‐amplified neuroblastoma

7 Dec 2020

Abstract excerpt

Abstract Here we sought metabolic alterations specifically associated withMYCNamplification as nodes to indirectly target theMYCNoncogene. Liquid chromatography‐mass spectrometry‐based proteomics identified seven proteins consistently correlated with MYCN in proteomes from 49 neuroblastoma biopsies and 13 cell lines. Among these was phosphoglycerate dehydrogenase (PHGDH), the rate‐limiting enzyme in de novo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33284994
DOI: 10.1002/ijc.33423

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN ‐amplified neuroblastomaPMID 33284994Read ↗

MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting NeuroblastomaSemantic proximity Read ↗

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastomaSemantic proximity Read ↗

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastomaSemantic proximity Read ↗

N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastomaSemantic proximity Read ↗

Metabolic targeting of neuroblastoma, an updateSemantic proximity Read ↗

Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma ProgressionSemantic proximity Read ↗

Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming CellsSemantic proximity Read ↗

Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine PathwaysSemantic proximity Read ↗

PHGDH is a targetable driver of PDAC progressionSemantic proximity Read ↗

MYCN Amplifications and Metabolic Rewiring in NeuroblastomaSemantic proximity Read ↗

Polyamine Metabolism Is Sensitive to Glycolysis Inhibition in Human Neuroblastoma CellsSemantic proximity Read ↗

Joint metabolomics and transcriptomics analysis systematically reveal the impact of MYCN in neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.